Objective:To study the effects of basal insulin combined with Sitagliptin Phosphate Tablets on blood glucose control, oxidative stress and inflammatory response.Methods: Type 2 diabetic patients with poor blood glucos...Objective:To study the effects of basal insulin combined with Sitagliptin Phosphate Tablets on blood glucose control, oxidative stress and inflammatory response.Methods: Type 2 diabetic patients with poor blood glucose control after metformin monotherapy in our hospital between March 2015 and July 2017 were selected as the research subjects and divided into two groups by random number table method. The experimental group received metformin + basal insulin + sitagliptin treatment, while control group were treated with metformin + glimepiride. The levels of glycosylated hemoglobin as well as the contents of oxidative stress indexes and inflammatory response indexes were measured before treatment and 3 months after treatment. Results: Compared with those before treatment, glycosylated hemoglobin levels, serum AGEs, MDA, CRP, TNF-α, IL-6, IL-8 and VCAM-1 contents as well as peripheral blood Nrf2, HO-1, NOX2 and NOX4 expression intensity of both groups were significantly decreased while serum SOD and CAT contents were significantly increased 3 months after treatment, and glycosylated hemoglobin level, serum AGEs, MDA, CRP, TNF-α, IL-6, IL-8 and VCAM-1 contents as well as peripheral blood Nrf2, HO-1, NOX2 and NOX4 expression intensity of experimental group 3 months after treatment were significantly lower than those of control group whereas serum SOD and CAT contents were significantly higher than those of control group (P<0.05).Conclusion: Basal insulin combined with Sitagliptin Phosphate Tablets can improve the blood glucose control condition and reduce the oxidative stress and inflammatory response in type 2 diabetic patients with poor blood glucose control after metformin monotherapy.展开更多
文摘Objective:To study the effects of basal insulin combined with Sitagliptin Phosphate Tablets on blood glucose control, oxidative stress and inflammatory response.Methods: Type 2 diabetic patients with poor blood glucose control after metformin monotherapy in our hospital between March 2015 and July 2017 were selected as the research subjects and divided into two groups by random number table method. The experimental group received metformin + basal insulin + sitagliptin treatment, while control group were treated with metformin + glimepiride. The levels of glycosylated hemoglobin as well as the contents of oxidative stress indexes and inflammatory response indexes were measured before treatment and 3 months after treatment. Results: Compared with those before treatment, glycosylated hemoglobin levels, serum AGEs, MDA, CRP, TNF-α, IL-6, IL-8 and VCAM-1 contents as well as peripheral blood Nrf2, HO-1, NOX2 and NOX4 expression intensity of both groups were significantly decreased while serum SOD and CAT contents were significantly increased 3 months after treatment, and glycosylated hemoglobin level, serum AGEs, MDA, CRP, TNF-α, IL-6, IL-8 and VCAM-1 contents as well as peripheral blood Nrf2, HO-1, NOX2 and NOX4 expression intensity of experimental group 3 months after treatment were significantly lower than those of control group whereas serum SOD and CAT contents were significantly higher than those of control group (P<0.05).Conclusion: Basal insulin combined with Sitagliptin Phosphate Tablets can improve the blood glucose control condition and reduce the oxidative stress and inflammatory response in type 2 diabetic patients with poor blood glucose control after metformin monotherapy.